"Ozempic face" is the hollowing of the cheeks, temples and under-eye area that follows rapid weight loss on a GLP-1 medication. The drug does not act on your face. Appetite suppression puts you in a calorie deficit, subcutaneous fat leaves every depot including the facial fat pads, and skin retraction lags behind, so the result reads as age rather than leanness. Mounjaro face, Wegovy face, Zepbound face and GLP-1 face are the same effect under different brand names.
What almost nothing written about it covers is the lean starting point. Those articles describe the population the drugs were trialled in and the population dermatologists see. I started at 96.0 kg and 13.0% body fat, and the facial change arrived far earlier in the process than any of that writing suggests it would.
What is Ozempic face, exactly?
The face holds fat in discrete compartments: the cheeks, the temples, the area under the eyes, and smaller pads around the mouth and jaw. Those compartments are what give a face its fullness and what hold the skin out from underneath. In a sustained calorie deficit they shrink along with every other fat depot in the body.
Lose it slowly, over a year, and the skin retracts alongside it. You just look leaner. Lose it in ten weeks and the skin has not caught up with the volume that left, so the result reads as age rather than leanness: flatter cheeks, shadow at the temples, deeper nasolabial folds, a hollow under the eye that was not there before.
A 2025 systematic review in Aesthetic Surgery Journal Open Forum put this in clinical terms, describing morphological changes that resemble advanced aging following GLP-1 mediated weight loss, and cataloguing the surgical and non-surgical options practitioners offer for it. The same paper notes the search behaviour that follows: people looking up "Ozempic face" go on to look up facial fillers and plastic surgeons.
Does the drug cause it, or does the weight loss?
Semaglutide has no mechanism that acts on your face. None. It suppresses appetite, you eat less, you run a deficit, and fat leaves your body in the order and proportion your genetics dictate. Some of that fat is in your face. That is the whole causal chain, and the naming hides it.
Which is why the brand-name variants are all describing one phenomenon:
- Ozempic face and Wegovy face: semaglutide, the same molecule at different licensed doses.
- Mounjaro face and Zepbound face: tirzepatide, a dual GIP/GLP-1 agonist. Larger average weight loss at maximum dose, roughly 21% versus semaglutide's 15% in the registration trials, so the facial change can appear sooner. Same mechanism, faster clock.
- GLP-1 face: the generic term, and the most accurate of the four.
People who lose thirty kilos through surgery, illness, or a disciplined year of training get the same face. It had no brand name before 2023 because no single product was producing it in enough people at once to be worth naming.
Why does it arrive earlier when you start lean?
Fat loss is not a queue. You do not empty the abdominal stores first and reach the face last. Every depot draws down together, in proportions your genetics set and you do not get a vote on.
What changes with the starting point is the buffer. At 35% body fat the facial pads are thick, so five kilos takes a slice off something that had plenty. At 13% those pads are already thin. Same five kilos, same proportional draw, completely different face at the end of it.
Across my first protocol I went from 96.0 kg and 13.0% body fat to approximately 90 kg and 11.3% in five weeks on tirzepatide. Six kilos. That is a rounding error next to the twenty and thirty kilo losses in the case reports, and it was already enough to change the face.
Note for the photo set: the before and after images belong here, with dates and the weight at each. Matched lighting and angle, or they prove nothing.
What did my own timeline look like?
The documented protocol, for context on when the change happened relative to the dosing:
- February 2026: started tirzepatide (Mounjaro) at 2.5 mg per week, from 96.0 kg and 13.0% body fat.
- Through March 2026: five-week protocol, ending at approximately 90 kg and 11.3% body fat.
- April 2026: femur fracture. Medication on hold through surgery and early bone healing, training gone entirely.
- 29 June 2026: prescription moved to semaglutide (Ozempic), because no clinic in Saigon reliably stocks tirzepatide.
- 3 July to 10 August 2026: titration from 15 units to 40 units across five weeks.
The fracture matters to the facial question more than it looks. A femur fracture takes away resistance training at exactly the point where resistance training is the thing protecting lean mass. Weight that comes off during forced inactivity is a worse composition of weight than weight that comes off while you are still lifting, and that shows up in the face along with everywhere else.
To fill in from your own observation: when you first noticed the change, who else noticed and what they said, and whether it tracked the dose increases or the weight itself.
What actually changes the outcome?
Nothing protects facial fat selectively. There is no exercise, cream, or supplement that directs a deficit away from one depot, and anything sold on that promise is being sold on a mechanism that does not exist. What is real:
- Rate of loss. The strongest lever by a distance. Skin retraction is slow and continuous, fat loss on a high dose is not, and the gap between the two is what you see in the mirror. Half a kilo a week gives the skin a chance. A kilo and a half a week does not.
- The lowest dose that works. Titrating to the maximum tolerated dose optimises for the fastest number on the scale, which is the wrong target if you care what you look like at the end of it. My own escalation to 40 units produced no additional appetite coverage over the lower doses, so the higher dose was buying nothing and would have cost the same face.
- Protein and resistance training. These do not save the facial pads. They change the proportion of lean mass in what you lose, which is the difference between looking drawn and looking lean at the same scale weight.
- Time at a stable weight. It looks worst in the weeks right after a sharp drop. Hold the weight and the skin catches up, and some of what looked permanent turns out not to have been. Do not judge your face mid-titration.
Sleep and sun exposure get mentioned constantly in the consumer coverage. They are real inputs to skin quality over years. They are not going to offset a kilo and a half a week.
What would I not do?
I would not cut or stop the dose without telling the physician who prescribed it. The facial change is a legitimate thing to raise in that appointment, and a doctor who understands why an athlete is on this will work with a slower titration. Doing it silently just means the next dose decision gets made on bad information.
I would not chase it with facial exercises. The facial fat compartments are fat, not muscle, and there is no training stimulus that refills them.
On fillers and surgical options, I have no experience and no standing. The systematic review documents that both exist and that demand for them tracks the search interest in this term. Whether either is right for a particular face is a conversation with a dermatologist or plastic surgeon who can examine you, and I would want that conversation to happen at a stable weight rather than mid-deficit.
Is it worth it?
For someone taking a GLP-1 for type 2 diabetes or clinically significant obesity, this is not a close call. The metabolic benefit and the cosmetic cost are not in the same category, and treating them as comparable does a disservice to people whose health genuinely depends on the medication.
For an already-lean athlete using it to reach a body composition target, it is a real trade and worth naming as one. You are spending facial volume to buy race weight. The aggressive protocol gets the number faster and takes more face to do it. The slower protocol costs weeks and keeps more of it. I would rather spend the weeks.
For the full protocol and how the medication has interacted with training, see my complete GLP-1 journey. For the lean mass side of the same problem, see the muscle preservation protocol, and for why I stayed low rather than escalating, see microdosing GLP-1 as an endurance athlete.
Frequently Asked Questions
What is Ozempic face?
"Ozempic face" is the gaunt, hollowed appearance that can follow rapid weight loss on semaglutide: flattened cheeks, hollowing at the temples and under the eyes, more visible nasolabial folds, and skin that reads as looser because there is less volume underneath holding it out. The term was coined by Paul Jarrod Frank, a cosmetic dermatologist in New York, and reached a wide audience through the New York Times on 24 January 2023. It is a description of an appearance, not a diagnosis, and Ozempic is not doing anything to your face directly. A 2025 systematic review in Aesthetic Surgery Journal Open Forum describes it as morphological change resembling advanced aging that follows GLP-1 mediated weight loss.
Is Mounjaro face different from Ozempic face?
No. Mounjaro face, Wegovy face, Zepbound face and GLP-1 face all describe the same appearance, and the mechanism is identical: subcutaneous fat leaving the face because you are in a sustained calorie deficit. The brand names differ because the marketing does. Tirzepatide (Mounjaro, Zepbound) tends to produce faster and larger total weight loss than semaglutide (Ozempic, Wegovy) at maximum dose, roughly 21% versus 15% in the registration trials, so if anything the facial effect can show up sooner on tirzepatide. That is a difference in rate, not in kind.
Does Ozempic face go away?
Partly, and it depends what you mean. Facial fat comes back if you regain the weight, which is not the outcome most people want. If you hold the lower weight, the volume does not return on its own, because the fat that provided it is gone. What does improve over the following months is the skin: some of the apparent looseness immediately after fast loss is skin that has not yet retracted, and that continues to adapt. In my own case the first weeks after each sharp drop looked worse than the weeks that followed at a stable weight.
How do you avoid Ozempic face?
You cannot protect facial fat specifically, because there is no mechanism for spot-reducing or spot-sparing a fat depot. What is genuinely under your control is the rate of loss and the composition of what you lose. A slower deficit gives skin time to adapt and takes less total fat off in any given month. Adequate protein and hard resistance training protect lean mass, which changes what the rest of your body looks like at the same scale weight. And dose discipline matters: the lowest dose that produces the loss you want will take your face down more gently than the maximum tolerated dose.
Why does Ozempic face show up faster in lean people?
Because there is less to spare. Subcutaneous facial fat is a small depot to begin with, and it is drawn down along with everything else during a deficit. Someone starting at 35% body fat has a large buffer, so their face changes late in the process. I started at 13.0% body fat, and at that level the facial pads are already thin, so the change is visible after a few kilos rather than after twenty. This is the part that is genuinely underreported: most of the clinical and dermatology writing on Ozempic face describes patients who began with a great deal more fat than a trained endurance athlete carries.
Should I stop my GLP-1 because of facial changes?
That is a question for your physician, not for a website, and the honest answer depends on why you are taking it. If the medication is treating type 2 diabetes or clinically significant obesity, the metabolic benefit is not in the same weight class as a cosmetic concern. If you are an already-lean athlete using it for a body composition target, then facial volume is a real cost worth weighing against a real benefit, and slowing the protocol is usually a better lever than stopping it. What I would not do is quietly cut the dose without telling the doctor who prescribed it.
Ready to Train Smarter?
Get personalized training zones, race predictions, and performance insights with our free calculators.
